GleamWall
中文EN

ANL Adlai Nortye Group Ltd. IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1944552 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY52.5%
TTM EPS YoY78.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-103.2%
ROA-51.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets64.2%
Debt / equity0.00x
Current ratio1.41x
Interest coverage-27.23x

Cash quality & payout

Operating cash flow / net income1.00x
Accruals ratio-0.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20242024-12-31FY20232023-12-31
Income statement
Revenue—$5.00M
R&D expense$44.91M$58.15M
SG&A expense$9.95M$15.29M
Operating income-$52.93M-$72.55M
Interest expense$1.94M$791,000
Pretax income-$51.87M-$109.23M
Income tax—$643,000
Net income-$51.87M-$109.23M
EBITDA-$52.42M-$72.09M
EPS (basic)-0.54-2.52
EPS (diluted)-0.54-2.52
Weighted avg. shares (diluted)95.78M43.34M
Balance sheet
Cash & equivalents$60.90M$91.49M
Current assets$64.06M$101.19M
PP&E, netmay include right-of-use assets (IFRS)$1.74M$2.65M
Intangibles$40,000$63,000
Total assets$71.27M$130.19M
Current liabilities$45.36M$49.67M
Short-term debt$26.33M$30.36M
Total liabilities$45.78M$55.14M
Shareholders' equity$25.48M$75.05M
Cash flow statement
Operating cash flow-$51.82M-$56.65M
Capital expenditure$170,000$200,000
Free cash flow-$51.99M-$56.85M
Investing cash flow$28.07M-$10.95M
Financing cash flow-$6.58M$116.24M
Depreciation & amortization$510,000$465,000
Stock-based compensation$2.45M$4.33M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.